Amgen Inc
AMGN295.525USD
+0.425+0.14%
Market hours （ET）Quotes delayed by 15 min
158.90BMarket Cap
26.78P/E TTM
More Details of Amgen Inc Company
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
Ticker SymbolAMGN
Company nameAmgen Inc
IPO dateJun 17, 1983
Founded at1986
CEOMr. Robert A. (Bob) Bradway
Number of employees28000
Security typeOrdinary Share
Fiscal year-endJun 17
AddressOne Amgen Center Drive
CityTHOUSAND OAKS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code91320-1799
Phone18054471000
Websitehttps://www.amgen.com/
Ticker SymbolAMGN
IPO dateJun 17, 1983
Founded at1986
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+1.52%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+3.06%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
41.70K
+6.10%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+4.94%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+6.57%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
7.78K
-16.17%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
7.57K
+11.97%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
7.35K
+12.36%
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
7.30K
+5.21%
Ms. Amy E. Miles
Ms. Amy E. Miles
Independent Director
Independent Director
4.84K
+20.06%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
566.37K
+1.52%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
69.05K
+3.06%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
41.70K
+6.10%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
17.19K
+4.94%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.93K
+6.57%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
7.78K
-16.17%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Other products
1.65B
20.21%
Prolia
1.10B
13.49%
Repatha
656.00M
8.05%
XGEVA
566.00M
6.95%
Enbrel
510.00M
6.26%
Other
3.67B
45.05%
By RegionUSD
Name
Revenue
Proportion
US
5.34B
65.55%
ROW
2.09B
25.64%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Other products
1.65B
20.21%
Prolia
1.10B
13.49%
Repatha
656.00M
8.05%
XGEVA
566.00M
6.95%
Enbrel
510.00M
6.26%
Other
3.67B
45.05%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.79%
State Street Global Advisors (US)
5.43%
BlackRock Institutional Trust Company, N.A.
5.30%
Capital World Investors
3.11%
Capital International Investors
2.81%
Other
73.56%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.79%
State Street Global Advisors (US)
5.43%
BlackRock Institutional Trust Company, N.A.
5.30%
Capital World Investors
3.11%
Capital International Investors
2.81%
Other
73.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.54%
Investment Advisor/Hedge Fund
19.35%
Research Firm
4.93%
Pension Fund
2.27%
Bank and Trust
1.90%
Sovereign Wealth Fund
1.19%
Hedge Fund
0.91%
Insurance Company
0.64%
Individual Investor
0.17%
Other
16.11%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
4438
451.31M
83.93%
+5.48M
2025Q1
4519
453.49M
84.33%
+5.91M
2024Q4
4466
443.40M
82.54%
+89.78K
2024Q3
4316
438.01M
81.42%
-5.13M
2024Q2
4284
437.79M
81.61%
-4.94M
2024Q1
4192
436.25M
81.40%
-5.11M
2023Q4
4150
435.28M
81.36%
+42.25K
2023Q3
3990
429.94M
80.36%
-4.48M
2023Q2
3936
426.14M
79.65%
-4.34M
2023Q1
3951
427.29M
80.00%
-4.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
52.63M
9.79%
+145.69K
+0.28%
Mar 31, 2025
State Street Global Advisors (US)
29.18M
5.43%
-254.42K
-0.86%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
28.50M
5.3%
-289.51K
-1.01%
Mar 31, 2025
Capital World Investors
16.70M
3.11%
+10.21M
+157.12%
Mar 31, 2025
Capital International Investors
15.13M
2.81%
+2.92M
+23.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
12.73M
2.37%
+252.31K
+2.02%
Mar 31, 2025
PRIMECAP Management Company
12.39M
2.3%
-613.83K
-4.72%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
12.21M
2.27%
-999.66K
-7.57%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
11.11M
2.07%
-33.38K
-0.30%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
8.73M
1.62%
+352.70K
+4.21%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
VanEck Biotech ETF
16.62%
FT Vest DJIA Dogs 10 Target Income ETF
9.94%
Invesco Nasdaq Biotechnology ETF
8.43%
ProShares Ultra Nasdaq Biotechnology
7.64%
iShares Biotechnology ETF
7.59%
Invesco Dow Jones Industrial Average Dividend ETF
5.11%
Invesco Pharmaceuticals ETF
5%
Invesco Biotechnology & Genome ETF
4.86%
Proshares Ultra DOW 30
4.19%
Global X Dow 30 Covered Call ETF
4.19%
View more
VanEck Biotech ETF
Proportion16.62%
FT Vest DJIA Dogs 10 Target Income ETF
Proportion9.94%
Invesco Nasdaq Biotechnology ETF
Proportion8.43%
ProShares Ultra Nasdaq Biotechnology
Proportion7.64%
iShares Biotechnology ETF
Proportion7.59%
Invesco Dow Jones Industrial Average Dividend ETF
Proportion5.11%
Invesco Pharmaceuticals ETF
Proportion5%
Invesco Biotechnology & Genome ETF
Proportion4.86%
Proshares Ultra DOW 30
Proportion4.19%
Global X Dow 30 Covered Call ETF
Proportion4.19%
Dividend
A total of
21.35B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 10, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 07, 2025
Feb 14, 2025
Oct 25, 2024
AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024
Nov 18, 2024
Dec 09, 2024
Nov 18, 2024
Aug 02, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 06, 2024
Aug 16, 2024
Mar 06, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024
May 17, 2024
Jun 07, 2024
May 16, 2024
Dec 12, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024
Feb 16, 2024
Mar 07, 2024
Feb 15, 2024
Oct 24, 2023
AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023
Nov 17, 2023
Dec 08, 2023
Nov 16, 2023
Aug 01, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 08, 2023
Aug 17, 2023
Mar 07, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Dec 12, 2022
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 08, 2023
Feb 14, 2023
Oct 28, 2022
AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 08, 2022
Nov 16, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
